127 related articles for article (PubMed ID: 23398249)
1. Thromboembolic events associated with immunoglobulin treatment.
Funk MB; Gross N; Gross S; Hunfeld A; Lohmann A; Guenay S; Hanschmann KM; Keller-Stanislawski B
Vox Sang; 2013 Jul; 105(1):54-64. PubMed ID: 23398249
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study.
Ramírez E; Romero-Garrido JA; López-Granados E; Borobia AM; Pérez T; Medrano N; Rueda C; Tong HY; Herrero A; Frías J
Thromb Res; 2014 Jun; 133(6):1045-51. PubMed ID: 24731561
[TBL] [Abstract][Full Text] [Related]
3. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
4. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
[TBL] [Abstract][Full Text] [Related]
5. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
[TBL] [Abstract][Full Text] [Related]
6. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
[TBL] [Abstract][Full Text] [Related]
7. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
8. IVIg-exposure and thromboembolic event risk: findings from the UK Biobank.
Kapoor M; Hunt I; Spillane J; Bonnett LJ; Hutton EJ; McFadyen J; Westwood JP; Lunn MP; Carr AS; Reilly MM
J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):876-885. PubMed ID: 35688633
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products.
Germishuizen WA; Gyure DC; Stubbings D; Burnouf T
Biologicals; 2014 Sep; 42(5):260-70. PubMed ID: 25096922
[TBL] [Abstract][Full Text] [Related]
10. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment.
Taylor E; Vu D; Legare C; Keene D
Transfusion; 2015 Jul; 55 Suppl 2():S23-7. PubMed ID: 26174894
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy.
Ammann EM; Jones MP; Link BK; Carnahan RM; Winiecki SK; Torner JC; McDowell BD; Fireman BH; Chrischilles EA
Blood; 2016 Jan; 127(2):200-7. PubMed ID: 26443622
[TBL] [Abstract][Full Text] [Related]
13. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010.
Daniel GW; Menis M; Sridhar G; Scott D; Wallace AE; Ovanesov MV; Golding B; Anderson SA; Epstein J; Martin D; Ball R; Izurieta HS
Transfusion; 2012 Oct; 52(10):2113-21. PubMed ID: 22448967
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
15. [Adverse events in 1395 infusions with different intravenous gammaglobulin products].
Malbrán A; Larrauri B; Juri MC; Fernández Romero DS
Medicina (B Aires); 2013; 73(5):433-7. PubMed ID: 24152399
[TBL] [Abstract][Full Text] [Related]
16. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
[TBL] [Abstract][Full Text] [Related]
17. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
18. Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria.
Mitzel-Kaoukhov H; Staubach P; Müller-Brenne T
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):253-8. PubMed ID: 20377115
[TBL] [Abstract][Full Text] [Related]
19. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
